NASDAQ:SLDB

Solid Biosciences Stock Insider Trading

Healthcare > Biotechnology

Buy SLDB

*Your capital is at risk

$6.85

+0.270 (+4.10%)

At Close: Jun 03, 2026

Solid Biosciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 7.33. In total, the insiders bought 13.49M and sold 403.46K SLDB shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	7.33
● Buy	13.49M shares
● Sell	403.46K shares
76% Buy Activity Weak Positive Correlation
Sell Signal Low Confidence Feb 04, 2026 Analysis Breakdown: Weakened by a contradictory positive Insider Power Score. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 29, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Brooks Gabriel Chief Medical Officer	Officer	207 450 Value: $1.37M
Jan 29, 2026 Buy	Restricted Stock Units A-Award	Brooks Gabriel Chief Medical Officer	Officer	103 750 Value: $684.8K
Jan 29, 2026 Buy	Common Stock M-Exempt	Brooks Gabriel Chief Medical Officer	Officer	58 847 Value: $388.4K
Jan 29, 2026 Buy	Restricted Stock Units A-Award	Howton David T Chief Operating Officer	C-Suite Officer	105 100 Value: $693.7K
Jan 29, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Herzich Paul Chief Technology Officer	Officer	170 000 Value: $1.12M
Jan 29, 2026 Buy	Performance Stock Units M-Exempt	Herzich Paul Chief Technology Officer	Officer	54 925 Value: $362.5K
Jan 29, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Ganot Ilan Director	Director	70 900 Value: $467.9K
Jan 29, 2026 Buy	Restricted Stock Units A-Award	Ganot Ilan Director	Director	35 450 Value: $234.0K
Jan 28, 2026 Sell	Common Stock S-Sale	Ganot Ilan Director	Director	191 Value: $1K
Jan 27, 2026 Buy	Common Stock M-Exempt	Ganot Ilan Director	Director	3 884 Value: $25.5K
Jan 27, 2026 Buy	Common Stock M-Exempt	Ganot Ilan Director	Director	389 Value: $3K
Jan 27, 2026 Buy	Restricted Stock Units M-Exempt	Ganot Ilan Director	Director	3 884 Value: $25.5K
Jan 13, 2026 Sell	Common Stock S-Sale	Tan Kevin CFO & Treasurer	C-Suite Officer	5 704 Value: $30.1K
Jan 09, 2026 Buy	Restricted Stock Units M-Exempt	Tan Kevin CFO & Treasurer	C-Suite Officer	11 250 Value: $59.5K
Jan 09, 2026 Buy	Common Stock M-Exempt	Tan Kevin CFO & Treasurer	C-Suite Officer	11 250 Value: $59.5K
Jan 06, 2026 Buy	Common Stock M-Exempt	Smith Ian F Director	Director	4 573 Value: $25.1K
Jan 06, 2026 Buy	Restricted Stock Units M-Exempt	Smith Ian F Director	Director	4 573 Value: $25.1K
Jan 05, 2026 Sell	Common Stock S-Sale	Ganot Ilan Director	Director	1 053 Value: $6K
Jan 03, 2026 Buy	Common Stock M-Exempt	Ganot Ilan Director	Director	2 994 Value: $20.5K
Jan 03, 2026 Buy	Restricted Stock Units M-Exempt	Ganot Ilan Director	Director	2 994 Value: $20.5K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Smith Ian F Director	Director	18 012 Value: $98.2K
Jan 02, 2026 Buy	Restricted Stock Units A-Award	Smith Ian F Director	Director	13 761 Value: $75.0K
Dec 03, 2025 Sell	Common Stock S-Sale	Howton David T Chief Operating Officer	C-Suite Officer	4 932 Value: $25.2K
Dec 02, 2025 Buy	Common Stock M-Exempt	Cumbo Alexander President And CEO	CEO / President	28 612 Value: $145.9K
Dec 02, 2025 Buy	Restricted Stock Units M-Exempt	Howton David T Chief Operating Officer	C-Suite Officer	13 051 Value: $66.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT SOLID BIOSCIENCES INC.

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technol...

Read Full Profile Here